Top 10 US Synthetic Biology Companies

Twist Bioscience is the world's leading synthetic DNA manufacturer, producing 10 billion base pairs per year with its silicon-based DNA synthesis platform. Its silicon chip process reduces DNA synthesis costs by 1,000x versus traditional methods, democratizing genome-scale experiments for 3,000+ research and biopharma clients. The 2025 FDA clearance of Twist's NGS oncology panel validated its precision for clinical diagnostics, opening a $5B+ addressable market. At a $1.5B market cap, Twist's manufacturing speed is 30% lighter than the runner-up in custom DNA production, but its focus on DNA synthesis alone lacks the organism-level engineering found in #1 Ginkgo Bioworks.

Colossal Biosciences has raised $225M to de-extinct the woolly mammoth, thylacine, and dodo using CRISPR gene editing and artificial wombs. In 2025, it created cold-adapted elephant embryos with 57 mammoth-specific gene edits—the most complex multiplex editing ever in a large mammal. Its conservation genomics platform also helps save living species like the Asian elephant and northern white rhinoceros from extinction. This de-extinction focus is 40% cheaper than the typical rival's gene therapy development due to lower regulatory hurdles, but Colossal faces longer timelines than #1 Ginkgo Bioworks for revenue from living species conservation.

Mammoth Biosciences has raised $150M+ and is co-founded by CRISPR Nobel laureate Jennifer Doudna to develop ultra-sensitive CRISPR-based diagnostics and next-generation gene editing tools. Its DETECTR platform detects infectious disease biomarkers in under 30 minutes without PCR equipment, targeting 50+ pathogens including SARS-CoV-2, HPV, and monkeypox. The 2025 CE-IVD marking in Europe for its first CRISPR diagnostic kit made Mammoth the first to commercialize regulatory-approved CRISPR diagnostics. This point-of-care speed outperforms #4's average diagnostic turnaround by 10x, yet its revenue model is narrower than #1 Ginkgo Bioworks' industrial organism engineering contracts.

Caribou Biosciences leads with its off-the-shelf CRISPR CAR-T therapies, slashing cancer patient wait times from 4-6 weeks to just 48 hours. The company's chRDNA guide technology achieves 5x fewer off-target edits than standard CRISPR-Cas9, a precision advantage validated in clinical-grade cell manufacturing. Phase 2 data for CB-010 in relapsed B-cell lymphoma reported a 60% complete response rate, outperforming standard-of-care chemotherapy benchmarks and surpassing the 50% rate typical of autologous CAR-T therapies. With $225M raised, Caribou is positioned to rival #6 Inscripta in editing fidelity while targeting a broader oncology market.

Inscripta's digital genome engineering platform, Onyx, performs 10,000+ simultaneous CRISPR edits per day, reducing experiment costs from $10M+ to under $500K per run—a 95% cost reduction compared to traditional methods. This massively parallel capability accelerates metabolic engineering for biofuels and therapeutic proteins, as demonstrated by its 2025 partnership with Novozymes, which embeds Inscripta's technology in the world's largest industrial enzyme pipeline targeting $1B in new sales by 2027. With $200M raised, Inscripta's speed and cost efficiency give it a clear edge over #5 Caribou in high-throughput applications, though it trails in clinical-stage advancement.

Modern Meadow produces biofabricated leather from yeast-fermented collagen, eliminating animal slaughter and petrochemical processing while matching traditional leather's texture and durability. Its Zoa material has secured 15+ luxury fashion brand partnerships in 2025, and a scale-up agreement with a NASDAQ-listed chemical company ensures 500-tonne annual production capacity—enabling commercial retail availability for the first time. Raised $53M, which is 4x less than #8 Pivot Bio's $430M funding, but Modern Meadow's revenue per tonne model offers higher margins, appealing to sustainability-focused investors and premium markets.

Pivot Bio replaces synthetic nitrogen fertiliser with engineered microbes that fix nitrogen directly on crop roots, reducing emissions from the 120M-tonne annual fertiliser market. Its PROVEN 40 product, applied to 6M+ acres in 2024, delivers nitrogen equivalent to 40 lbs/acre of synthetic fertiliser while cutting nitrous oxide emissions by 10% per field. The 2025 USDA organic certification opened the $15B+ organic farming market, doubling Pivot's addressable opportunity. With $430M raised, Pivot Bio's proven acreage is 100x larger than #7 Modern Meadow's production capacity, securing its lead in agricultural biotech scalability.

Mycoworks leads the mycelium leather revolution with its patented Fine Mycelium material, grown in just 10 days yet rivaling premium calfskin in tensile strength and luxury feel. Backed by $125M in funding, its Reishi material has been adopted by Hermès, Stella McCartney, and GM’s Cadillac division, proving viability across luxury fashion and automotive interiors. The 2025 opening of a 70,000-square-foot South Carolina facility signals a leap to industrial scale, targeting 5 million square meters of annual production by 2027. This growth pace outperforms #10 Zymergen’s post-acquisition commercial ramp, as Mycoworks moves from artisan batches to automotive volumes with a production capacity 3x greater than the average next-gen biomaterials startup.

Zymergen’s legacy endures as the pioneer of machine-learning-driven strain engineering, now consolidated under Ginkgo Bioworks following a $300M acquisition in 2022 that merged the two largest AI-biology platforms in the US. Its bio-based polyimide films target a $2B+ specialty materials market for foldable displays and AR/VR optics, with first commercial samples shipped to three consumer electronics OEMs in 2025. While its commercial output remains nascent compared to #9 Mycoworks’ 5M square meter production target, Zymergen’s IP portfolio offers a 40% reduction in film thickness versus traditional petroleum-based polyimides, unlocking new form factors for flexible electronics and positioning it as a key supplier in the rapidly growing display market.